Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Infectious Diseases›Condition·Updated Jun 5, 2026·v1

Ceftriaxone

Ceftriaxone is a third-generation cephalosporin used for a wide range of serious infections, notable for its once-daily dosing and high CSF penetration. It is strictly contraindicated in neonates due to fatal calcium interactions and kernicterus risk.

High Evidence93 references·4,877 words·20 min read·v1
antibioticscephalosporinsmeningitisgonorrheainfectious-diseases

Quick Reference

RxDrug of choiceBacterial meningitis (empiric), Uncomplicated Gonorrhea, Lyme Borreliosis (neurological).
AltAlternativesCefotaxime (preferred in neonates), Cefepime (if Pseudomonas suspected).
⊘AvoidNeonates <28 days receiving calcium IV; Hyperbilirubinemic neonates; Severe cephalosporin allergy.
DxTest of choiceCulture and Sensitivity (MIC determination).
ScKey scoreChild-Pugh Score (to monitor in combined renal/hepatic failure).
→When to referSuspected ceftriaxone-induced encephalopathy; Refractory sepsis; Complex SJS/TEN reactions.
A versatile, once-daily 3rd-gen cephalosporin essential for meningitis and gonorrhea, but carries a black-box risk for fatal calcium precipitates in neonates.
Ceftriaxone is a cornerstone third-generation [[cephalosporin]] antibiotic distinguished by its broad-spectrum activity against Gram-positive and Gram-negative pathogens and a uniquely long half-life that permits once-daily dosing. It functions by inhibiting bacterial cell wall synthesis through high-affinity binding to penicillin-binding proteins (PBPs), leading to osmotic rupture and cell death. Clinically, it is a first-line agent for life-threatening infections including bacterial [[meningitis]], community-acquired pneumonia, and complicated intra-abdominal infections. Beyond its antimicrobial properties, ceftriaxone modulates central nervous system homeostasis by upregulating glutamate transporters, offering potential neuroprotective benefits. However, its use is strictly limited in neonates due to fatal interactions with calcium-containing solutions and the risk of bilirubin displacement, and clinicians must remain vigilant for biliary pseudolithiasis and neurotoxicity in patients with renal impairment.

Overview and Recommendations

Key Facts

  • •Ceftriaxone is a parenteral third-generation that provides robust coverage against a wide array of aerobic Gram-negative organisms and many Gram-positive cocci, though it lacks activity against , species, and methicillin-resistant (MRSA). Its molecular structure includes a triazine side chain at the 3-position, which confers a prolonged elimination half-life of 5.8 to 8.7 hours, significantly longer than most other beta-lactams.
  • •The primary mechanism of action involves the irreversible acylation of transpeptidase enzymes (penicillin-binding proteins, specifically PBP 2 and 3), which prevents the cross-linking of chains essential for bacterial cell wall integrity. This inhibition triggers the activation of endogenous autolysins, resulting in rapid bactericidal activity that is strictly time-dependent, meaning efficacy is maximized when the free drug concentration remains above the minimum inhibitory concentration (fT > MIC) for 40% to 70% of the dosing interval.
  • •Pharmacokinetic stability is maintained through a unique dual-elimination pathway where approximately 33% to 67% of the drug is excreted unchanged in the urine, while the remainder is secreted into the bile and eventually eliminated in the feces. This compensatory mechanism allows for standard dosing (up to 2 g daily) in patients with isolated renal or hepatic failure without the need for adjustment, provided both organs are not simultaneously severely impaired.
  • •Non-antimicrobial pharmacologic effects include the potent induction of Excitatory Amino Acid Transporter 2 (EAAT2/GLT-1) in , which enhances the clearance of from the synaptic cleft. This mechanism is currently being investigated for neuroprotection in conditions involving excitotoxicity, such as neuropathic pain, epilepsy, and certain neurodegenerative pathways, although its impact on long-term synaptic plasticity remains a subject of preclinical debate.
  • •The drug is highly protein-bound (85% to 95%) in a concentration-dependent manner; as plasma levels rise above 300 mcg/mL, the protein-binding sites become saturated, increasing the free (active) fraction of the drug. This non-linear pharmacokinetics means that higher doses (e.g., 2 g) result in a disproportionately higher concentration of free drug available for tissue penetration, which is particularly relevant in the treatment of central nervous system infections.

Clinical Use

  • •Suspect bacterial in patients presenting with fever, headache, and nuchal rigidity; initiate ceftriaxone 2 g IV every 12 hours (or 100 mg/kg/day in pediatrics) to ensure therapeutic cerebrospinal fluid (CSF) concentrations, which reach 5.6 to 6.4 mcg/mL in the presence of inflamed meninges.
  • •Order ceftriaxone 1 g to 2 g IV once daily for the management of (CAP), typically in combination with a macrolide like to cover atypical pathogens. While 2 g is common for severe presentations, clinical evidence suggests 1 g daily is non-inferior for most hospitalized patients with CAP.
  • •Administer a single intramuscular dose of 500 mg for the treatment of uncomplicated urogenital, rectal, or pharyngeal . Note that clinical guidelines have shifted toward this higher dose (and sometimes 1 g in patients weighing ≥150 kg) to overcome increasing minimum inhibitory concentrations (MICs) globally.
  • •Utilize ceftriaxone 2 g IV every 24 hours as a primary component of empiric therapy for or when the source is suspected to be the urinary or respiratory tract. Pre-hospital administration by emergency medical services has been shown to significantly reduce the time to first antibiotic dose without increasing adverse event rates.
  • •Employ a synergistic combination of 2 g every 4 hours plus ceftriaxone 2 g every 12 hours for the treatment of caused by Enterococcus faecalis. This regimen leverages ceftriaxone's ability to saturate PBP 2 and 3, which enhances the binding of ampicillin to PBPs 4 and 5, providing an effective alternative to aminoglycoside-containing regimens.
  • •Initiate surgical prophylaxis with a single 1 g IV dose administered 0.5 to 2 hours prior to the start of contaminated or potentially contaminated procedures to reduce the risk of postoperative site infections.
  • •Manage acute gastroesophageal variceal hemorrhage in patients with by administering 1 g IV daily for 2 to 7 days. A short 2-day course has been shown to be non-inferior to longer courses for preventing early rebleeding and infection in this high-risk population.
  • •Treat complicated skin and skin structure infections (SSSI) with 1 g to 2 g IV once daily, targeting Streptococcus pyogenes and methicillin-susceptible Staphylococcus aureus (MSSA). For infections confirmed to be MSSA, ensure the dose is at least 2 g daily to achieve optimal target attainment, though remains the preferred agent for MSSA bacteremia.
  • •Consider ceftriaxone 2 g IV daily for the treatment of neurological or late-stage (Lyme borreliosis). While oral is often sufficient for early localized disease, parenteral ceftriaxone remains the standard for central nervous system involvement or refractory arthritis.
  • •Add anaerobic coverage, such as 500 mg every 8 hours, when using ceftriaxone for intra-abdominal infections or perforated appendicitis, as ceftriaxone lacks reliable activity against Bacteroides fragilis and other gut anaerobes.
  • •Monitor for clinical response in patients with or severe shigellosis, where ceftriaxone 1 g to 2 g daily (or 50 mg/kg in children) is a standard parenteral option, though resistance in XDR Shigella strains is an emerging concern.
  • •Avoid using ceftriaxone as monotherapy for hospital-acquired pneumonia or healthcare-associated infections where or multi-drug resistant Gram-negative rods are suspected; in these cases, broader agents like or are required.

Safety

  • •Do NOT administer ceftriaxone to neonates (≤28 days) who require calcium-containing intravenous solutions, such as or Lactated Ringer's. Fatal crystalline precipitates of ceftriaxone-calcium can form in the lungs and kidneys; these fatalities have occurred even when different infusion lines and different sites were used.
  • •Avoid use in premature or hyperbilirubinemic neonates because ceftriaxone competes with bilirubin for albumin binding sites. This displacement can lead to increased free bilirubin levels and subsequent (kernicterus).
  • •Monitor for biliary "pseudolithiasis" (biliary sludge or stones), particularly in pediatric patients or those receiving high doses for prolonged periods. This occurs due to the precipitation of ceftriaxone-calcium salts in the gallbladder and is typically reversible upon drug discontinuation, though it can occasionally cause symptomatic cholecystitis.
  • •Screen for a history of severe beta-lactam hypersensitivity before administration. While cross-reactivity with penicillins is low (~1-3%), ceftriaxone is contraindicated in patients with a history of anaphylaxis, SJS/TEN, or other severe reactions to any .
  • •Discontinue therapy immediately if signs of immune-mediated occur. This rare but potentially fatal complication involves the development of antibodies against the drug-erythrocyte complex; if anemia develops during treatment, ceftriaxone should be stopped until the cause is identified.
  • •Assess for neurotoxicity, including , myoclonus, and non-convulsive status epilepticus, especially in elderly patients or those with severe renal impairment. These effects are often associated with excessive dosing relative to renal function and typically resolve within days of stopping the drug.
  • •Evaluate patients for -associated diarrhea (CDAD) if they develop new-onset diarrhea during or up to two months after therapy. Ceftriaxone significantly alters the gut microbiome and is a well-known trigger for C. diff overgrowth.
  • •Monitor renal function and serum potassium if co-administering with other nephrotoxic agents, although ceftriaxone itself is generally not nephrotoxic. No dose adjustment is needed for isolated renal impairment (CrCl > 10 mL/min) unless the dose exceeds 2 g per day.
  • •Check for hematologic abnormalities such as eosinophilia (6%), thrombocytosis (5%), or leukopenia (2%), which are generally mild and asymptomatic but may require monitoring during long-term therapy (e.g., for osteomyelitis).
  • •Ensure that intravenous lines are thoroughly flushed with a compatible fluid (e.g., 0.9% Sodium Chloride) between ceftriaxone and calcium-containing infusions in patients older than 28 days to prevent physical incompatibility and precipitation in the IV tubing.
  • •Be aware of the sodium content (83 mg or 3.6 mEq per gram of ceftriaxone), which may be clinically significant for patients on strict sodium restriction, such as those with severe or advanced cirrhosis with ascites.
  • •Avoid ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections if possible; meta-analyses suggest a 57% increase in 30-day all-cause mortality compared to or antistaphylococcal penicillins.
  • •Instruct patients to report any signs of a secondary infection, such as oral candidiasis or vaginal yeast infections, as the broad-spectrum nature of the drug can lead to fungal overgrowth.
  • •Use caution when co-administering with vitamin K antagonists (e.g., ), as alterations in gut flora and potential interference with vitamin K metabolism can enhance anticoagulant effects and increase the risk of bleeding.

Board Review — High Yield

  • •Kernicterus — Ceftriaxone displaces bilirubin from albumin, making it contraindicated in hyperbilirubinemic neonates.
  • •Biliary Pseudolithiasis — Reversible gallbladder sludge/stones caused by ceftriaxone-calcium precipitation, common in pediatrics.
  • •Dual Elimination — Excreted via both renal (33-67%) and biliary pathways; no dose adjustment needed for isolated renal or hepatic failure.
  • •Calcium Incompatibility — Fatal precipitates in lungs/kidneys of neonates if co-administered with IV calcium (e.g., TPN, Ringer's).
  • •EAAT2 Induction — Non-antimicrobial mechanism involving upregulation of glutamate transporters, providing neuroprotection.
  • •MSSA Mortality — Associated with higher 30-day mortality (OR 1.57) compared to cefazolin for MSSA bacteremia.
  • •Gonorrhea Dosing — Current standard is 500 mg IM single dose (up to 1 g if ≥150 kg) due to rising resistance.
  • •PBP 2/3 — The primary molecular targets for ceftriaxone's bactericidal cell wall inhibition.
  • •Enterococcus Synergy — Combined with ampicillin to treat E. faecalis endocarditis via PBP saturation.

Deep Dive — Evidence Details

References

  1. [1]

    Karataş Gezen G, Karaaslan O. “Randomized controlled trial on the effects of different antibiotic regimens in preterm premature rupture of membranes after 34 weeks.” Medicine (2026). PMID: 41650076 ↗

    L1RCTCited in: Introduction and Chemical Structure, Special Populations and Contraindications
  2. [2]

    Sankar J, Haribabu PPK, Singaravelu Suganya AGK. “Fusobacterium brain abscess as a complication of sinusitis in an immunocompetent adolescent: A case report.” World journal of clinical pediatrics (2026). PMID: 42220957 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  3. [3]

    Huang L, Xi Y, Yu M et al.. “Post-endoscopic neurosurgical Candida albicans meningoencephalitis diagnosed by targeted next-generation sequencing: a case report.” Frontiers in medicine (2026). PMID: 42180747 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  4. [4]

    Dai L, Zhan W, Huang X et al.. “Refractory multiple brain abscesses caused by Prevotella loescheii and Porphyromonas gingivalis: successful endoscopic lavage and drainage: a case report and review of the literature.” Frontiers in medicine (2026). PMID: 41709890 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  5. [5]

    Liu J, Chen Y, Sheng X et al.. “Case Report: Nocardia farcinica infectious arthritis and myositis in an immunocompromised host: diagnostic and management challenges.” Frontiers in medicine (2026). PMID: 41647522 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  6. [6]

    Logan N, Birhane MG, McDonald SL et al.. “Emergence of Extensively Drug-Resistant Shigellosis - United States, 2011-2023.” MMWR. Morbidity and mortality weekly report (2026). PMID: 41955161 ↗

    L2OTHERCited in: Introduction and Chemical Structure
  7. [7]

    Lee CC, Chen CL, Su ST et al.. “Molecular epidemiological characterization of invasive extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from infants less than 3 months old in East Asia.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41862085 ↗

    L2OTHERCited in: Introduction and Chemical Structure
  8. [8]

    Kedir BM, Mohammed C, Abdurahman A et al.. “Prevalence and antimicrobial susceptibility profiles of Klebsiella Pneumoniea isolated from cases of bovine mastitis in Maya City, Eastern Hararghe, Ethiopia.” BMC microbiology (2026). PMID: 41792616 ↗

    L2OTHERCited in: Introduction and Chemical Structure
  9. [9]

    Sharma VD, Singla A, Chaudhary M et al.. “Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects.” AAPS PharmSciTech (2016). PMID: 26644225 ↗

    L2RCTCited in: Mechanism of Action
  10. [10]

    Wang JL, Ye CH, Teng ZF et al.. “Targeting complement C3/C3aR pathway restores rejuvenation factor PF4 and mitigates neurocognitive impairments in age-related perioperative neurocognitive disorders.” Molecular psychiatry (2025). PMID: 40659841 ↗

    L5OTHERCited in: Mechanism of Action
  11. [11]

    Postnikova TY, Malkin SL, Zakharova MV et al.. “Ceftriaxone Treatment Weakens Long-Term Synaptic Potentiation in the Hippocampus of Young Rats.” International journal of molecular sciences (2021). PMID: 34445137 ↗

    L5OTHERCited in: Mechanism of Action
  12. [12]

    Zaitsev AV, Malkin SL, Postnikova TY et al.. “Ceftriaxone Treatment Affects EAAT2 Expression and Glutamatergic Neurotransmission and Exerts a Weak Anticonvulsant Effect in Young Rats.” International journal of molecular sciences (2019). PMID: 31766528 ↗

    L5OTHERCited in: Mechanism of Action
  13. [13]

    Pottabathini R, Kumar A, Bhatnagar A et al.. “Ameliorative potential of pioglitazone and ceftriaxone alone and in combination in rat model of neuropathic pain: Targeting PPARγ and GLT-1 pathways.” Pharmacological reports : PR (2016). PMID: 26721358 ↗

    L5OTHERCited in: Mechanism of Action
  14. [14]

    McDermott AJ, Higdon KE, Muraglia R et al.. “The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.” Immunology (2015). PMID: 25399934 ↗

    L5OTHERCited in: Mechanism of Action
  15. [15]

    Maltecca F, Baseggio E, Consolato F et al.. “Purkinje neuron Ca2+ influx reduction rescues ataxia in SCA28 model.” The Journal of clinical investigation (2015). PMID: 25485680 ↗

    L5OTHERCited in: Mechanism of Action
  16. [16]

    Lee MR, Ruby CL, Hinton DJ et al.. “Striatal adenosine signaling regulates EAAT2 and astrocytic AQP4 expression and alcohol drinking in mice.” Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2013). PMID: 23032072 ↗

    L5OTHERCited in: Mechanism of Action
  17. [17]

    Goldstein LH, Gabin A, Fawaz A et al.. “Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia.” Pharmacoepidemiology and drug safety (2015). PMID: 26238864 ↗

    L2OTHERCited in: Mechanism of Action
  18. [18]

    Liu XX, Yang L, Shao LX et al.. “Endothelial Cdk5 deficit leads to the development of spontaneous epilepsy through CXCL1/CXCR2-mediated reactive astrogliosis.” The Journal of experimental medicine (2020). PMID: 31699822 ↗

    L5OTHERCited in: Mechanism of Action
  19. [19]

    Lee S, Kim SK, Lee DY et al.. “Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats.” Antimicrobial agents and chemotherapy (2006). PMID: 16641464 ↗

    L5OTHERCited in: Mechanism of Action
  20. [20]

    Versporten A, Coenen S, Adriaenssens N et al.. “European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe (1997-2009).” The Journal of antimicrobial chemotherapy (2011). PMID: 22096063 ↗

    L2OTHERCited in: Mechanism of Action
  21. [21]

    Kokai-Kun JF, Roberts T, Coughlin O et al.. “The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.” Antimicrobial agents and chemotherapy (2017). PMID: 28052855 ↗

    L2RCTCited in: Pharmacokinetics (LADME), Dose and Administration
  22. [22]

    Comce MH, Weersink RA, Beuers U et al.. “Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review.” The Journal of antimicrobial chemotherapy (2024). PMID: 39289819 ↗

    L2SR_OBSCited in: Pharmacokinetics (LADME)
  23. [23]

    Hartman SJF, Brüggemann RJ, Orriëns L et al.. “Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.” Clinical pharmacokinetics (2020). PMID: 31432468 ↗

    L2SR_OBSCited in: Pharmacokinetics (LADME)
  24. [24]

    Zhao Y, Cudkowicz ME, Shefner JM et al.. “Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.” Journal of clinical pharmacology (2014). PMID: 24771634 ↗

    L2RCTCited in: Pharmacokinetics (LADME)
  25. [25]

    Richards GA, Elliott E, Shaddock EJ et al.. “A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis.” South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (2013). PMID: 24300626 ↗

    L1RCTCited in: Pharmacokinetics (LADME)
  26. [26]

    Kanesaka I, Kong FYS, Vanbaelen T et al.. “An overview of potential combination therapies with ceftriaxone as a treatment for gonorrhoea.” Expert review of anti-infective therapy (2025). PMID: 40374502 ↗

    L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
  27. [27]

    Derbie A, Mekonnen D, Woldeamanuel Y et al.. “Azithromycin resistant gonococci: a literature review.” Antimicrobial resistance and infection control (2020). PMID: 32811545 ↗

    L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
  28. [28]

    Kong FYS, Horner P, Unemo M et al.. “Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review.” The Journal of antimicrobial chemotherapy (2019). PMID: 30649333 ↗

    L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
  29. [29]

    Daudon M, Frochot V, Bazin D et al.. “Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.” Drugs (2018). PMID: 29264783 ↗

    L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
  30. [30]

    Gergs U, Clauss T, Ihlefeld D et al.. “Pharmacokinetics of ceftriaxone in plasma and bone of patients undergoing hip or knee surgery.” The Journal of pharmacy and pharmacology (2014). PMID: 24941934 ↗

    L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
  31. [31]

    Zhanel GG, Chung P, Adam H et al.. “Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.” Drugs (2014). PMID: 24352909 ↗

    L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
  32. [32]

    Futagi Y, Ito Y, Nakade J et al.. “Ceftriaxone-induced encephalopathy in a patient with a solitary kidney.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2022). PMID: 35843497 ↗

    L4CASE_REPORTCited in: Pharmacokinetics (LADME)
  33. [33]

    Luckey A, Balasegaram M, Barbee LA et al.. “Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.” Lancet (London, England) (2026). PMID: 41391465 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  34. [34]

    Srivastava S, Gumbo T. “Systematic and quantitative analyses of hollow fiber model of Mycobacterium abscessus lung disease studies and new dosing recommendations.” Microbiology spectrum (2026). PMID: 42012229 ↗

    L5SR_OBSCited in: Pharmacodynamics
  35. [35]

    Costa M, Incristi A, Lindsay J et al.. “Effectiveness of antibiotic prophylaxis for ventilator-associated pneumonia in acute brain injury: a systematic review and meta-analysis.” Infection (2026). PMID: 41379388 ↗

    L1SR_OBSCited in: Pharmacodynamics, Adverse Effects and Toxicity
  36. [36]

    Jiang TT, Zhang XB, Zhao PZ et al.. “App-Based Training Module on Guiding Physicians' Prescription for Antibiotic Treatment of Gonorrhea: Cluster Randomized Controlled Trial.” JMIR mHealth and uHealth (2026). PMID: 41813422 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use
  37. [37]

    Zhang CX, Nuzhat S, Islam MR et al.. “Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis.” Clinical and translational science (2026). PMID: 41454572 ↗

    L2RCTCited in: Pharmacodynamics, Indications and Clinical Use, Special Populations and Contraindications
  38. [38]

    Tao X, Wang J, Rao J et al.. “Empirical antibiotic therapy for spontaneous intracerebral hemorrhage-associated pneumonia: an ICU-based single-centered retrospective cohort study.” BMC infectious diseases (2025). PMID: 41402792 ↗

    L3COHORTCited in: Pharmacodynamics
  39. [39]

    Perera V, Wardlow L, Sobhanie MM et al.. “Daptomycin versus beta-lactam based therapy for the treatment of enterococcal endocarditis and other endovascular infections: a retrospective cohort study.” BMC infectious diseases (2025). PMID: 41121008 ↗

    L3COHORTCited in: Pharmacodynamics
  40. [40]

    Tarigan MB, Saragih RM, Tarigan KA et al.. “Antimicrobial resistance and empirical antibiotic use in diabetic foot infections: A retrospective study from Indonesia.” Narra J (2025). PMID: 41743866 ↗

    L4COHORTCited in: Pharmacodynamics
  41. [41]

    Maraolo AE, Nobile M, Gentile I. “Ceftriaxone for methicillin-susceptible Staphylococcus aureus bloodstream infections is associated with increased short-term mortality: a systematic review and meta-analysis.” Annals of medicine (2026). PMID: 42112603 ↗

    L2SR_OBSCited in: Pharmacodynamics, Adverse Effects and Toxicity
  42. [42]

    Visser M, Wolffs PFG, Hoebe CJPA et al.. “Antimicrobial susceptibility patterns of Neisseria gonorrhoeae across anatomical sites within and between individuals in the Netherlands: a retrospective observational study.” The Lancet. Microbe (2026). PMID: 42235568 ↗

    L2OTHERCited in: Pharmacodynamics
  43. [43]

    Shu Z, Cao J, Li H et al.. “Efficacy and safety of first- and second-line antibiotics for cellulitis and erysipelas: a network meta-analysis of randomized controlled trials.” Archives of dermatological research (2024). PMID: 39240378 ↗

    L1SR_MA_RCTCited in: Indications and Clinical Use
  44. [44]

    Choi SH, Cesar A, Snow TAC et al.. “Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.” International journal of antimicrobial agents (2023). PMID: 37385561 ↗

    L1SR_MA_RCTCited in: Indications and Clinical Use
  45. [45]

    Liu M, Fan Y, Chen J et al.. “Efficacy and Safety of Treatments for Different Stages of Syphilis: a Systematic Review and Network Meta-Analysis of Randomized Controlled Trials and Observational Studies.” Microbiology spectrum (2022). PMID: 36377935 ↗

    L2SR_MA_RCTCited in: Indications and Clinical Use
  46. [46]

    Heysell SK, Mpagama SG, Nuwagira E et al.. “Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial.” The Lancet. Infectious diseases (2026). PMID: 41619753 ↗

    L1RCTCited in: Indications and Clinical Use
  47. [47]

    Gagnon DJ, Burkholder KM, Weissman AJ et al.. “Ceftriaxone to Prevent Early-Onset Pneumonia in Comatose Patients Following Out-of-Hospital Cardiac Arrest: A Pilot Randomized Controlled Trial and Resistome Assessment (PROTECT).” Chest (2026). PMID: 40885534 ↗

    L1RCTCited in: Indications and Clinical Use
  48. [48]

    Alam El-Din LW, El-Bassiouny NA, Khedr WM et al.. “The potential impact of clindamycin on neurosurgery patients: a randomized controlled trial.” Inflammopharmacology (2025). PMID: 40549322 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  49. [49]

    Ross JDC, Wilson J, Workowski KA et al.. “Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.” Lancet (London, England) (2025). PMID: 40245902 ↗

    L1RCTCited in: Indications and Clinical Use
  50. [50]

    Cudini D, Smith K, Shao J et al.. “Blood culture collection and administration of intravenous ceftriaxone by paramedics in patients with suspected sepsis (the pass trial).” Emergency medicine Australasia : EMA (2025). PMID: 40098585 ↗

    L1RCTCited in: Indications and Clinical Use
  51. [51]

    Sluis WM, de Jonge JC, Reinink H et al.. “Impact of central adjudication of the score on the modified Rankin Scale in an international, randomized, acute stroke trial.” European stroke journal (2025). PMID: 39968909 ↗

    L1RCTCited in: Indications and Clinical Use
  52. [52]

    Gupta A, Agarwal S, Sharma S et al.. “Antibiotic prophylaxis to prevent infection in patients with Child-Pugh A cirrhosis with upper gastrointestinal bleed: an open label randomised controlled trial.” Hepatology international (2025). PMID: 39751759 ↗

    L1RCTCited in: Indications and Clinical Use
  53. [53]

    Sluis WM, de Jonge JC, Reinink H et al.. “Metoclopramide to Prevent Pneumonia in Patients With Stroke and a Nasogastric Tube: Data From the PRECIOUS Trial.” Stroke (2024). PMID: 39129650 ↗

    L2RCTCited in: Indications and Clinical Use
  54. [54]

    Zheng T, Wang R, Wu C et al.. “Assessing morinidazole for surgical site infection in class III wounds prevention: a multi-centre, randomized, single-blind, parallel-controlled study.” The Journal of hospital infection (2024). PMID: 38964506 ↗

    L1RCTCited in: Indications and Clinical Use
  55. [55]

    Lo GH, Yeh JH, Tseng CH et al.. “A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage.” The American journal of gastroenterology (2024). PMID: 38526204 ↗

    L1RCTCited in: Dose and Administration
  56. [56]

    Rob F, Klubalová B, Nyčová E et al.. “Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2020). PMID: 31419483 ↗

    L1RCTCited in: Dose and Administration, Dose Modification
  57. [57]

    Ross JDC, Brittain C, Cole M et al.. “Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial.” Lancet (London, England) (2019). PMID: 31056291 ↗

    L1RCTCited in: Dose and Administration, Dose Modification
  58. [58]

    Berende A, ter Hofstede HJ, Vos FJ et al.. “Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease.” The New England journal of medicine (2016). PMID: 27028911 ↗

    L1RCTCited in: Dose and Administration
  59. [59]

    Westendorp WF, Vermeij JD, Brouwer MC et al.. “Pre-Stroke Use of Beta-Blockers Does Not Lower Post-Stroke Infection Rate: An Exploratory Analysis of the Preventive Antibiotics in Stroke Study.” Cerebrovascular diseases (Basel, Switzerland) (2016). PMID: 27701170 ↗

    L2RCTCited in: Dose and Administration
  60. [60]

    Vermeij JD, Westendorp WF, Roos YB et al.. “Preventive Ceftriaxone in Patients with Stroke Treated with Intravenous Thrombolysis: Post Hoc Analysis of the Preventive Antibiotics in Stroke Study.” Cerebrovascular diseases (Basel, Switzerland) (2016). PMID: 27336314 ↗

    L2RCTCited in: Dose and Administration
  61. [61]

    Sudo RYU, Câmara MCC, Kieling SV et al.. “Shorter versus longer duration of antibiotic treatment in children with bacterial meningitis: a systematic review and meta-analysis.” European journal of pediatrics (2024). PMID: 37870611 ↗

    L1SR_OBSCited in: Dose and Administration
  62. [62]

    Telles JP, Cieslinski J, Gasparetto J et al.. “Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis.” Expert review of anti-infective therapy (2019). PMID: 31179786 ↗

    L1SR_OBSCited in: Dose and Administration, Dose Modification
  63. [63]

    Jaiswal N, Singh M, Kondel R et al.. “Feasibility and efficacy of gentamicin for treating neonatal sepsis in community-based settings: a systematic review.” World journal of pediatrics : WJP (2016). PMID: 26830306 ↗

    L2SR_OBSCited in: Dose and Administration, Dose Modification
  64. [64]

    Chen MY, McNulty A, Avery A et al.. “Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial.” The Lancet. Infectious diseases (2019). PMID: 31196813 ↗

    L1RCTCited in: Dose Modification
  65. [65]

    Abdulla A, Ewoldt TMJ, Hunfeld NGM et al.. “The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.” BMC infectious diseases (2020). PMID: 31952493 ↗

    L5TRIAL_NONRANDOMCited in: Dose Modification
  66. [66]

    Le Turnier P, Navas D, Garot D et al.. “Tolerability of high-dose ceftriaxone in CNS infections: a prospective multicentre cohort study.” The Journal of antimicrobial chemotherapy (2019). PMID: 30698733 ↗

    L2TRIAL_NONRANDOMCited in: Dose Modification
  67. [67]

    Usta M, Erkan T, Cokugras FC et al.. “High doses of methylprednisolone in the management of caustic esophageal burns.” Pediatrics (2014). PMID: 24864182 ↗

    L1RCTCited in: Dose Modification
  68. [68]

    Roggeveen LF, Fleuren LM, Guo T et al.. “Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock - rationale and design of a multicenter randomized controlled superiority trial.” Trials (2019). PMID: 31852491 ↗

    L5TRIAL_NONRANDOMCited in: Dose Modification
  69. [69]

    Kang MH, Villablanca JG, Glade Bender JL et al.. “Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.” BMC research notes (2014). PMID: 24755475 ↗

    L4TRIAL_NONRANDOMCited in: Dose Modification
  70. [70]

    Jumaah MD, Shuhata MH, Al-Hamndawee DM et al.. “Role of intraoperative antibiotics wound irrigation in reducing surgical site infection following open appendectomy: a randomized controlled trial.” BMC surgery (2025). PMID: 40797247 ↗

    L1RCTCited in: Adverse Effects and Toxicity
  71. [71]

    Yaseen T, Alam K, Zawiah M et al.. “Ceftriaxone-induced cholelithiasis in pediatrics: pooled frequency, symptoms, and associated factors - systematic review and meta-analysis.” Italian journal of pediatrics (2025). PMID: 41074174 ↗

    L2SR_OBSCited in: Adverse Effects and Toxicity, Special Populations and Contraindications
  72. [72]

    Hu C, Li G, Chen D et al.. “Antibiotic for community-acquired pneumonia in hospitalized adults: A systematic review and Bayesian network meta-analysis.” Respiratory medicine (2025). PMID: 40404065 ↗

    L1SR_OBSCited in: Adverse Effects and Toxicity
  73. [73]

    Wang L, Wang L, Wei Z et al.. “Incidence and Clinical Significance of Drug-Induced Antibodies and Hemolytic Anemia Associated With Beta-Lactam Antibiotics: A Prospective Cohort Study.” Pharmacoepidemiology and drug safety (2026). PMID: 41629758 ↗

    L2COHORTCited in: Adverse Effects and Toxicity
  74. [74]

    Taniguchi J, Aso S, Matsui H et al.. “Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492536 ↗

    L3COHORTCited in: Adverse Effects and Toxicity
  75. [75]

    Taniguchi J, Aso S, Matsui H et al.. “Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study.” Pharmacoepidemiology and drug safety (2025). PMID: 40398875 ↗

    L3COHORTCited in: Adverse Effects and Toxicity
  76. [76]

    Häußler SM, Böttcher A, Betz CS et al.. “Acute mastoiditis in pediatric cochlear implant patients - a systematic review.” International journal of pediatric otorhinolaryngology (2025). PMID: 40976090 ↗

    L4SR_OBSCited in: Adverse Effects and Toxicity
  77. [77]

    Brust-Sisti L, Hu GY, Bridgeman M et al.. “Comparative Efficacy of High- and Low-Dose Ceftriaxone Regimens: A Systematic Review and Meta-Analysis.” The Annals of pharmacotherapy (2026). PMID: 40876848 ↗

    L1SR_OBSCited in: Adverse Effects and Toxicity
  78. [78]

    de Alencar ACV, Rego AGA, Chady CS et al.. “Alternative antibiotics for the treatment of bacterial meningitis in children: a systematic review of efficacy and safety.” Jornal de pediatria (2025). PMID: 40456280 ↗

    L1SR_OBSCited in: Adverse Effects and Toxicity
  79. [79]

    Dur Ş, Karadağ Aytemiz ÖE, Dinç S. “Comparative effectiveness of the Buzzy®, ShotBlocker® and Helfer skin tap technique in reducing pain and fear during pediatric intramuscular injections: A randomized controlled trial.” International emergency nursing (2026). PMID: 41512361 ↗

    L1RCTCited in: Adverse Effects and Toxicity
  80. [80]

    Lee YJ, Raviraj A, Tsao H. “A rare case of lung hernia associated with rib fractures and tension pneumothorax post cardiopulmonary resuscitation.” The American journal of emergency medicine (2026). PMID: 41762556 ↗

    L4CASE_REPORTCited in: Adverse Effects and Toxicity
  81. [81]

    Kumaraswamy M, Do C, Sakoulas G et al.. “Listeria monocytogenes endocarditis: case report, review of the literature, and laboratory evaluation of potential novel antibiotic synergies.” International journal of antimicrobial agents (2018). PMID: 29337066 ↗

    L4CASE_REPORTCited in: Drug Interactions
  82. [82]

    Baburaj G, Thomas L, Rao M. “Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.” Archives of medical research (2021). PMID: 33257051 ↗

    L5REVIEW_NARRATIVECited in: Drug Interactions
  83. [83]

    Beganovic M, Luther MK, Rice LB et al.. “A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29390132 ↗

    L5REVIEW_NARRATIVECited in: Drug Interactions
  84. [84]

    Yu X, Chu Z, Li J et al.. “Pharmacokinetic Drug-drug Interaction of Antibiotics Used in Sepsis Care in China.” Current drug metabolism (2021). PMID: 32990533 ↗

    L5SR_OBSCited in: Drug Interactions
  85. [85]

    Luque Paz D, Cañas MA, Cuervo G et al.. “In vitro activity of amoxicillin combined with oral cephalosporins against endocarditis-associated E. faecalis clinical isolates.” The Journal of antimicrobial chemotherapy (2026). PMID: 41967057 ↗

    L5OTHERCited in: Drug Interactions
  86. [86]

    Gonçalves IS, Soares JM, Bagnato VS et al.. “Targeting the Dynamic Susceptibility Window: Time-Sensitive Photodynamic Synergy With Antibiotics Against Streptococcus spp.” Lasers in surgery and medicine (2026). PMID: 41755426 ↗

    L5OTHERCited in: Drug Interactions
  87. [87]

    Damaceno NdS, Freire NML, Sturaro MC et al.. “Synergistic effects of ceftriaxone combined with BLI-489 against NDM-producing Klebsiella pneumoniae.” Microbiology spectrum (2026). PMID: 41733354 ↗

    L5OTHERCited in: Drug Interactions
  88. [88]

    Ashrin A, Hagenimana C, Jacquier H et al.. “Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium.” The Journal of antimicrobial chemotherapy (2026). PMID: 41247078 ↗

    L5OTHERCited in: Drug Interactions
  89. [89]

    Raffetin A, Roblot F, Lenormand C et al.. “Guidelines for Lyme borreliosis: treatment.” Infectious diseases now (2025). PMID: 41314469 ↗

    L1GUIDELINECited in: Special Populations and Contraindications
  90. [90]

    Alhusseini LB, Chaki SSG, Noshak MA et al.. “Cell wall-inhibiting antibiotics resistance in Streptococcus pneumoniae causing invasive diseases: a global systematic review and meta-analysis in pediatric populations.” Italian journal of pediatrics (2025). PMID: 41430708 ↗

    L2SR_OBSCited in: Special Populations and Contraindications
  91. [91]

    Armstrong J, Sriranjan J, Briatico D et al.. “Piperacillin/tazobactam versus ceftriaxone/metronidazole for children with perforated appendicitis: a systematic review and meta-analysis.” Pediatric surgery international (2025). PMID: 41186640 ↗

    L2SR_OBSCited in: Special Populations and Contraindications
  92. [92]

    Skripai A, Katz A, Lellouche J et al.. “Emerging Ceftriaxone Resistance in Paediatric Shigella sonnei: A 10-Year Retrospective Study.” Acta paediatrica (Oslo, Norway : 1992) (2026). PMID: 41555678 ↗

    L3COHORTCited in: Special Populations and Contraindications
  93. [93]

    Palma-Díaz EJ, Domínguez-Hermosillo JC, Tondopó-Guerrero J et al.. “Clinical and microbiological profile of invasive Salmonella disease in Mexico: a single-center retrospective study.” BMC infectious diseases (2025). PMID: 41455889 ↗

    L3COHORTCited in: Special Populations and Contraindications

Revision History

All updates applied to this page

Loading revisions…